Page last updated: 2024-12-07

4-desmethoxyverapamil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107928
SCHEMBL ID10453636
MeSH IDM0127209

Synonyms (29)

Synonym
benzeneacetonitrile, 3,4-dimethoxy-alpha-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-alpha-(1-methylethyl)-, (s)-
(-)-d 888
(-)-h3-desmethoxyverapamil
d888
4-dmv
d-888
unii-99eai85506
99eai85506 ,
4-desmethoxyverapamil
benzeneacetonitrile, 3,4-dimethoxy-alpha-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-alpha-(1-methylethyl)-, (-)-
PDSP1_001086
PDSP2_001070
gtpl2517
(-)-devapamil
(-)-desmethoxyverapamil
[3h](-)devapamil
(-)-d888
4-desmethoxyverapamil (4-dmv)
gtpl2515
(2s)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
93468-87-2
benzeneacetonitrile, 3,4-dimethoxy-.alpha.-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-.alpha.-(1-methylethyl)-, (s)-
devapamil, (-)-
desmethoxyverapamil, (-)-
benzeneacetonitrile, 3,4-dimethoxy-.alpha.-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-.alpha.-(1-methylethyl)-, (.alpha.s)-
SCHEMBL10453636
Q27077027
DTXSID401109924
(alphas)-3,4-dimethoxy-alpha-[3-[[2-(3-methoxyphenyl)ethyl]methylamino]propyl]-alpha-(1-methylethyl)benzeneacetonitrile

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"1 microM) to isolated hearts, or when given intravenously (2 mg kg-1 body weight 1 h before the animals were killed), anipamil displaced the dose-response curves for the positive inotropic effect of (0."( The Ca2+ -antagonist and binding properties of the phenylalkylamine, anipamil.
Dillon, JS; Nayler, WG, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)1990The Journal of pharmacology and experimental therapeutics, Nov, Volume: 255, Issue:2
SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)1991Molecular pharmacology, Nov, Volume: 40, Issue:5
Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations.
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)1995The Journal of biological chemistry, Sep-22, Volume: 270, Issue:38
Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels.
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)1996Molecular pharmacology, Nov, Volume: 50, Issue:5
Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (54.05)18.7374
1990's31 (41.89)18.2507
2000's2 (2.70)29.6817
2010's1 (1.35)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.77 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]